Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

NIH 1INDIV 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 7Other hematologic neoplasm 3Genitourinary 3Plasma cell 2Dermatologic 2CNS 2Tumor-Agnostic 1Thoracic 1Myeloid 1Breast 1

Conditions

Melanoma 2

Interventions

pembrolizumab 339Nivolumab 305Ipilimumab 274Cyclophosphamide 195aldesleukin 148Interleukin-2 110fludarabine phosphate 107trametinib 85Temozolomide 83fludarabine 81Dacarbazine 81dabrafenib 77Radiotherapy 75Biopsy 75Vemurafenib 71Imiquimod 53Bevacizumab 51sargramostim 50Magnetic Resonance Spectroscopy 50Specimen Handling 49Radiosurgery 49Peripheral Blood Stem Cell Transplantation 49Paclitaxel 49Aminolevulinic Acid 49binimetinib 48Carboplatin 48Blood Specimen Collection 47cemiplimab 46Cisplatin 453-ingenyl angelate 45

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
keyhole-limpet hemocyanin × Dermatologic × Clear all
NCT00124124 2015-02-13

Comparison of Dendritic Cells Versus Montanide as Adjuvants in a Melanoma Vaccine

Bhardwaj, Nina, M.D.

Phase 1 Completed
50 enrolled
Dermatologic

Melanoma

NCT00091143 2013-04-04

Fludarabine Followed by Vaccine Therapy and White Blood Cell Infusions in Treating Patients With Unresectable or Metastatic Melanoma

National Cancer Institute (NCI)

Phase 1 Completed
20 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡